Psychiatry Research
Volume 143, Issue 2 , Pages 111-120 , 30 August 2006

Serotonin 1a receptor and associated G-protein activation in schizophrenia and bipolar disorder

  • Laura Gray

      Affiliations

    • The Rebecca L. Cooper Research Laboratories, The Mental Health Research Institute of Victoria, 155 Oak Street, Parkville, Victoria 3052, Australia
    • Department of Pathology, The University of Melbourne, Parkville, Victoria 3010, Australia
    • ,
  • Elizabeth Scarr

      Affiliations

    • The Rebecca L. Cooper Research Laboratories, The Mental Health Research Institute of Victoria, 155 Oak Street, Parkville, Victoria 3052, Australia
    • Centre for Neuroscience, The University of Melbourne, Parkville, Victoria 3010, Australia
    • ,
  • Brian Dean

      Affiliations

    • The Rebecca L. Cooper Research Laboratories, The Mental Health Research Institute of Victoria, 155 Oak Street, Parkville, Victoria 3052, Australia
    • Department of Pathology, The University of Melbourne, Parkville, Victoria 3010, Australia
    • Department of Psychiatry, The University of Melbourne, Parkville, Victoria 3010, Australia
    • Department of Psychological Medicine, Monash University, Clayton, Victoria 3800, Australia
    • Corresponding Author InformationCorresponding author. The Rebecca L. Cooper Research Laboratories, The Mental Health Research Institute of Victoria, 155 Oak Street, Parkville, Victoria 3052, Australia. Tel.: +61 3 9389 3940; fax: +61 3 9387 5061.

Received 31 May 2005 ,Revised 22 August 2005 ,Accepted 16 September 2005.

References 

  1. Aleman A, Kahn RS, Selten JP. Sex differences in the risk of schizophrenia: evidence from meta-analysis. Archives of General Psychiatry. 2003;60:565–571
  2. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders. 4th ed.. Washington, DC: American Psychiatric Press; 1994;
  3. Arango V, Underwood MD, Gubbi AV, Mann JJ. Localized alterations in pre- and postsynaptic serotonin binding sites in the ventrolateral prefrontal cortex of suicide victims. Brain Research. 1995;688:121–3013
  4. Avissar S, Roitman G, Schreiber G. Differential effects of the antipsychotics haloperidol and clozapine on G protein measures in mononuclear leukocytes of patients with schizophrenia. Cellular and Molecular Neurobiology. 2001;21:799–811
  5. Burnet PW, Eastwood SL, Harrison PJ. [3H]WAY-100635 for 5-HT1A receptor autoradiography in human brain: a comparison with [3H]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia. Neurochemistry International. 1997;30:565–574
  6. Burt VK, Rasgon N. Special considerations in treating bipolar disorder in women. Bipolar Disorders. 2004;6:2–13
  7. Carrasco GA, Barker SA, Zhang Y, Damjanoska KJ, Sullivan NR, Garcia F, et al. Estrogen treatment increases the levels of regulator of G protein signaling-Z1 in the hypothalamic paraventricular nucleus: possible role in desensitization of 5-hydroxytryptamine1A receptors. Neuroscience. 2004;127:261–267
  8. Chou YH, Halldin C, Farde L. Occupancy of 5-HT1A receptors by clozapine in the primate brain: a PET study. Psychopharmacology (Berlin). 2003;166:234–240
  9. Cruz DA, Eggan SM, Azmitia EC, Lewis DA. Serotonin 1A receptors at the axon initial segment of prefrontal pyramidal neurons in schizophrenia. American Journal of Psychiatry. 2004;161:739–742
  10. Dean B, Tomaskovic-Crook E, Opeskin K, Keks N, Copolov D. No change in the density of the serotonin 1A receptor, the serotonin4 receptor or the serotonin transporter in the dorsolateral prefrontal cortex from subjects with schizophrenia. Neurochemistry International. 1999;34:109–115
  11. Dean B, Scarr E, Pavey G, Copolov D. Studies on serotonergic markers in the human hippocampus: changes in subjects with bipolar disorder. Journal of Affective Disorders. 2003;75:65–69
  12. Dowlatshahi D, MacQueen GM, Wang JF, Reiach JS, Young LT. G protein-coupled cyclic AMP signaling in postmortem brain of subjects with mood disorders: effects of diagnosis, suicide, and treatment at the time of death. Journal of Neurochemistry. 1999;73:1121–1126
  13. Emamghoreishi M, Li PP, Schlichter L, Parikh SV, Cooke R, Warsh JJ. Associated disturbances in calcium homeostasis and G protein-mediated cAMP signaling in bipolar I disorder. Biological Psychiatry. 2000;48:665–673
  14. Foster P. Neuroleptic equivalence. Pharmaceutical Journal. 1999;243:431–432
  15. Friedman E, Wang HY. Receptor-mediated activation of G proteins is increased in postmortem brains of bipolar affective disorder subjects. Journal of Neurochemistry. 1996;67:1145–1152
  16. Gundlah C, Alves SE, Clark JA, Pai LY, Schaeffer JM, Rohrer SP. Estrogen receptor-beta regulates tryptophan hydroxylase-1 expression in the murine midbrain raphe. Biological Psychiatry. 2005;57:938–942
  17. Gurevich EV, Joyce JN. Alterations in the cortical serotonergic system in schizophrenia: a postmortem study. Biological Psychiatry. 1997;42:529–545
  18. Hashimoto T, Nishino N, Nakai H, Tanaka C. Increase in serotonin 5-HT1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia. Life Sciences. 1991;48:355–363
  19. Heninger GR. Serotonin, sex, and psychiatric illness. Proceedings of the National Academy of Sciences of the United States of America. 1997;94:4823–4824
  20. Jakobsen SN, Wiborg O. Selective effects of long-term lithium and carbamazepine administration on G-protein subunit expression in rat brain. Brain Research. 1998;780:46–55
  21. Jope RS, Song L, Grimes CA, Pacheco MA, Dilley GE, Li X, et al. Selective increases in phosphoinositide signaling activity and G protein levels in postmortem brain from subjects with schizophrenia or alcohol dependence. Journal of Neurochemistry. 1998;70:763–771
  22. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. European Journal of Pharmacology. 2002;441:137–140
  23. Joyce JN, Shane A, Lexow N, Winokur A, Casanova MF, Kleinman JE. Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology. 1993;8:315–336
  24. Kaplan GB, Leite-Morris KA, Keith DJ. Differential effects of treatment with typical and atypical antipsychotic drugs on adenylyl cyclase and G proteins. Neuroscience Letters. 1999;273:147–150
  25. Karege F, Golaz J, Schwald M, Malafosse A. Lithium and haloperidol treatments differently affect the mononuclear leukocyte Gαs protein levels in bipolar affective disorder. Neuropsychobiology. 1999;39:181–186
  26. Kessing LV. Gender differences in the phenomenology of bipolar disorder. Bipolar Disorders. 2004;6:421–425
  27. Le Saux M, Di Paolo T. Changes in 5-HT1A receptor binding and G-protein activation in the rat brain after estrogen treatment: comparison with tamoxifen and raloxifene. Journal of Psychiatry & Neuroscience. 2005;30:110–117
  28. Lesch KP. Hallucinations: psychopathology meets functional genomics. Molecular Psychiatry. 1998;3:278–281
  29. Lopez-Figueroa AL, Norton CS, Lopez-Figueroa MO, Armellini-Dodel D, Burke S, Akil H, et al. Serotonin 5-HT1A, 5-HT1B, and 5-HT2A receptor mRNA expression in subjects with major depression, bipolar disorder, and schizophrenia. Biological Psychiatry. 2004;55:225–233
  30. Manji HK, Chen G, Shimon H, Hsiao JK, Potter WZ, Belmaker RH. Guanine nucleotide-binding proteins in bipolar affective disorder. Effects of long-term lithium treatment. Archives of General Psychiatry. 1995;52:135–144
  31. Minadeo N, Layden B, Amari LV, Thomas V, Radloff K, Srinivasan C, et al. Effect of Li+ upon the Mg2+-dependent activation of recombinant Giα1. Archives of Biochemistry and Biophysics. 2001;388:7–12
  32. Mize AL, Poisner AM, Alper RH. Estrogens act in rat hippocampus and frontal cortex to produce rapid, receptor-mediated decreases in serotonin 5-HT1A receptor function. Neuroendocrinology. 2001;73:166–174
  33. Newman-Tancredi A, Gavaudan S, Conte C, Chaput C, Touzard M, Verriele L, et al. Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPγS binding study. European Journal of Pharmacology. 1998;355:245–256
  34. Palego L, Marazziti D, Rossi A, Giannaccini G, Naccarato AG, Lucacchini A, et al. Apparent absence of aging and gender effects on serotonin 1A receptors in human neocortex and hippocampus. Brain Research. 1997;758:26–32
  35. Parsey RV, Oquendo MA, Simpson NR, Ogden RT, Van Heertum R, Arango V, et al. Effects of sex, age, and aggressive traits in man on brain serotonin 5-HT1A receptor binding potential measured by PET using [C-11]WAY-100635. Brain Research. 2002;954:173–182
  36. Rodriguez-Puertas R, Gonzalez-Maeso J, Meana JJ, Pazos A. Autoradiography of receptor-activated G-proteins in post mortem human brain. Neuroscience. 2000;96:169–180
  37. Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nature Reviews Drug Discovery. 2004;3:353–359
  38. Sanchez RL, Reddy AP, Centeno ML, Henderson JA, Bethea CL. A second tryptophan hydroxylase isoform, TPH-2 mRNA, is increased by ovarian steroids in the raphe region of macaques. Brain Research. Molecular Brain Research. 2005;135:194–203
  39. Schreiber G, Avissar S. Application of G-proteins in the molecular diagnosis of psychiatric disorders. Expert Reviews in Molecular Diagnosis. 2003;3:69–80
  40. Seeman MV. Women and schizophrenia. Medscape Womens Health. 2000;5:2
  41. Serres F, Muma NA, Raap DK, Garcia F, Battaglia G, Van de Kar LD. Coadministration of 5-hydroxytryptamine 1A antagonist WAY-100635 prevents fluoxetine-induced desensitization of postsynaptic 5-hydroxytryptamine 1A receptors in hypothalamus. Journal of Pharmacology and Experimental Therapeutics. 2000;294:296–301
  42. Simpson MD, Lubman DI, Slater P, Deakin JF. Autoradiography with [3H]8-OH-DPAT reveals increases in 5-HT(1A) receptors in ventral prefrontal cortex in schizophrenia. Biological Psychiatry. 1996;39:919–928
  43. Slater P, Doyle CA, Deakin JF. Abnormal persistence of cerebellar serotonin-1A receptors in schizophrenia suggests failure to regress in neonates. Journal of Neural Transmission. 1998;105:305–315
  44. Smith LJ, Henderson JA, Abell CW, Bethea CL. Effects of ovarian steroids and raloxifene on proteins that synthesize, transport, and degrade serotonin in the raphe region of macaques. Neuropsychopharmacology. 2004;29:2035–2045
  45. Sovago J, Dupuis DS, Gulyas B, Hall H. An overview on functional receptor autoradiography using [35S]GTPγS. Brain Research Reviews. 2001;38:149–164
  46. Spleiss O, van Calker D, Scharer L, Adamovic K, Berger M, Gebicke-Haerter PJ. Abnormal G protein αs- and αi2-subunit mRNA expression in bipolar affective disorder. Molecular Psychiatry. 1998;3:512–520
  47. Tauscher J, Kapur S, Verhoeff NP, Hussey DF, Daskalakis ZJ, Tauscher-Wisniewski S, et al. Brain serotonin 5-HT(1A) receptor binding in schizophrenia measured by positron emission tomography and [11C]WAY-100635. Archives of General Psychiatry. 2002;59:514–520
  48. Wang HY, Friedman E. Effects of lithium on receptor-mediated activation of G proteins in rat brain cortical membranes. Neuropharmacology. 1999;38:403–414
  49. Willmroth F, Spleiss O, Wiesmann K, Moser D, Atmanspacher R, van Calker D. Expression of G-proteins and regulators of G-protein signalling in neutrophils of patients with bipolar disorder: effects of mood stabilizers. Bipolar Disorders. 2002;4(Suppl 1):75–76
  50. Yang C-Q, Kitamura N, Nishino N, Shirakawa O, Nakai H. Isotype-specific G protein abnormalities in the left superior temporal cortex and limbic structures of patients with chronic schizophrenia. Biological Psychiatry. 1998;43:12–19

PII: S0165-1781(05)00292-1

doi: 10.1016/j.psychres.2005.09.010

Psychiatry Research
Volume 143, Issue 2 , Pages 111-120 , 30 August 2006

Article Tools

* Image Usage & Resolution